Table SI. Clinical characteristics of subgroups of patients with hypertension and control subjects.

| Characteristics | Control (n=90) | Hypertension | | |
| --- | --- | --- | --- | --- |
| | | Total (n=334) | Dipper (n=147) | Non-dipper (n=187) |
| Age (years) | 52.6±8.9 | 51.9±15.1 | 50.2±15.9 | 53.3±14.4 |
| Male sex | 45 (50.0) | 180 (53.9) | 87 (59.2) | 93 (49.7) |
| Smoking | 27 (30.0) | 157 (47.0) | 71 (48.3) | 86 (46.0) |
| Drinking | 15 (16.7) | 87 (26.0) | 40 (27.2) | 47 (25.1) |
| Obesity | 18 (20.0) | 220 (65.9)[a] | 91 (61.9)[a] | 131 (70.1)[a] |
| T2DM | 6 (6.7) | 94 (28.1)[a] | 32 (21.8)[a] | 62 (33.2)[a,b] |
| HLP | 21 (23.3) | 174 (52.1)[a] | 72 (49.0)[a] | 102 (54.5)[a] |
| SAHS | 0 (0.0) | 41 (12.3)[a] | 16 (10.9)[a] | 25 (12.9)[a] |
| Hypoxemia | 0 (0.0) | 38 (11.4)[a] | 15 (10.2)[a] | 23 (12.3)[a] |
| CAP | 6 (6.7) | 129 (38.6)[a] | 46 (31.3)[a,c] | 83 (44.4)[a,b] |
| HR (bpm) | 74.1±11.3 | 73.1±12.2 | 72.5±12.4 | 73.6±12.1 |
| SBP (mmHg) | 115±15 | 146±24[a] | 143±21[a] | 148±26[a] |
| DBP (mmHg) | 75±11 | 89±18[a] | 88±16[a] | 89±19[a] |
| BMI (kg/m$^2$) | 23.7±3.1 | 26.6±3.8[a] | 26.4±4.4[a] | 26.8±3.2[a] |
| Glu (mmol/l) | 4.8±0.5 | 5.9±1.5[a] | 5.9±1.5[a] | 5.9±1.6[a] |
| HbAlc (%) | 6.5±1.1 | 5.9±1.0[a] | 5.9±0.9[a] | 5.9±1.0[a] |
| TC (mmol/l) | 4.7±0.8 | 4.7±1.1 | 4.7±1.1 | 4.9±1.1 |
| TG (mmol/l) | 1.1±0.9 | 2.0±1.6[a] | 2.0±1.8[a] | 2.0±1.5[a] |
| HDL-C (mmol/l) | 1.2±0.4 | 1.1±0.3 | 1.1±0.3 | 1.1±0.3 |
| LDL-C (mmol/l) | 2.2±0.6 | 2.9±0.9[a] | 2.8±0.9[a] | 2.8±1.0[a] |
| CREA ($\mu$mol/l) | 63±13 | 74±32[a] | 74±30[a] | 75±33[a] |
| CRP (mg/l) | 0.7±0.9 | 2.7±4.6[a] | 2.8±4.4[a] | 2.7±4.7[a] |
| Hcy ($\mu$mol/l) | 11.3±6.1 | 14.5±8.5[a] | 14.3±7.9[a] | 14.7±8.9[a] |
| Medical treatments | | | | |
| ACEI/ARB | 9 (10.0) | 194 (58.1)[a] | 87 (59.2)[a] | 107 (57.2)[a] |
| β-blocker | 3 (3.3) | 137 (41.0)[a] | 63 (42.9)[a] | 74 (39.6)[a] |
| CCB | 1 (1.1) | 230 (68.9)[a] | 104 (70.7)[a] | 126 (67.4)[a] |
| Diuretics | 0 (0.0) | 91 (27.2)[a] | 41 (27.9)[a] | 51 (27.3)[a] |
| α-blocker | 1(1.1) | 20 (6.0)[a] | 6 (4.1)[a] | 14 (7.5)[a] |
| Statin | 16 (20.0) | 198 (57.7)[a] | 85 (57.8)[a] | 113 (57.7)[a] |

[a]P<0.05 vs. Control group, [b]P<0.05 vs. Dipper group, [c]P<0.05 vs. Total group. Values are expressed as n (%) or the mean ± standard deviation. T2DM, type 2 diabetes mellitus; HLP, hyperlipidemia; CAP, carotid atherosclerotic plaque; HR, heart rate; SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index; Glu, fasting glucose; HbAlc, hemoglobin a1c; TC, total cholesterol; TG, total triglycerides; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; CREA, creatinine; CRP, C-reactive protein; Hcy, homocysteine; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCB, calcium channel blocker; SAHS, sleep apnea hyponea syndrome.

Table SII. Data from ambulatory blood pressure monitoring in patients with hypertension and control subjects.

| Characteristics | Control (n=90) | Hypertension | | |
| | | Total (n=334) | Dipper (n=147) | Non-dipper (n=187) |
|---|---|---|---|---|
| CV-SBP | 11.0±1.6 | 11.2±7.5 | 11.3±3.8 | 11.0±9.4 |
| CV-DBP | 10.8±1.6 | 11.5±3.0 | 12.3±2.7 | 10.9±3.2 |
| NDR-SBP | 11.5±1.4 | 5.8±8.0[a] | 13.0±3.4[b] | 0.2±5.7[a-c] |
| NDR-DBP | 11.7±1.2 | 7.1±7.7[a] | 13.5±4.5[b] | 2.0±5.7[a-c] |
| A24h-SBP | 106±8 | 133±18[a] | 129±15[a] | 136±19[a] |
| A24h-DBP | 71±7 | 81±13[a] | 79±12[a] | 83±14[a] |
| AP-SBP | 115±13 | 135±18[a] | 133±18[a] | 136±17[a] |
| AP-DBP | 72±8 | 83±13[a] | 83±13[a] | 84±14[a] |
| PP-SBP | 96±9 | 128±21[a] | 115±19[a,b] | 135±21[a-c] |
| PP-DBP | 62±7 | 78±14[a] | 71±12[a,b] | 82±15[a-c] |

[a]P<0.05 vs. Control group, [b]P<0 05 vs. Total group, [c]P<0.05 vs. Dipper group. CV-SBP, 24-h coefficient of variation of SBP; NDR-SBP, night drop rate of SBP; A24h-MSBP, average SBP in 24 h; AP-SBP, average active period of SBP; PP-SBP, average passive period of SBP; SBP, systolic blood pressure; DBP, diastolic blood pressure.